Biromonol V-350mg Medisun Medicine Reducing Musculoskeletal Pain (5 blisters x 10 tablets)

ма атс: мозва02

Mechanism of reducing unpleasant and acute pain due to carioprodol muscle disease has not been determined.

Animal studies show that carisoprodol causes muscle relaxation by inhibiting the nerve transmission in the mesh of the brain and spinal cord.

Pharmacokinetics

absorption

Distribution

Carisoprodol quickly distributed into the central nervous system.

Metabolism

Carisoprodol is metabolized through CYP2C19 in the liver to form Meprobamat.

This enzyme shows genetic polymorphism (see patients with CYP2C19 reduced activity).

Elimination

Carisoprodol is eliminated through the kidneys and one part of the kidneys with a semi -duration of excretion about 2 hours. Meprobamat waste sale time is about 10 hours.

Sex: Carisoprodol's response in women is higher than men.

Patients with CYP2C19 reduced activity: Caution should be used in these patients.

Caution when using

sedation

Carisoprodol causes sedation and can reduce cognitive and/or exercise to be able to drive, operate machinery.

It is possible that the effect of the sedative effect of carisoprodol and other central neurological inhibitors (such as alcohol, benzodiazepine, opium, three -round antidepressants). Therefore, be careful with patients who are using alcohol and/or central neurological inhibitors. Do not use Carisoprodol and Meprobamat simultaneously.

Abuse, dependence and stop use

Carisoprodol abuse causes an overdose risk, which can lead to death, central neuropathy, respiratory failure, hypotension, brushes and other disorders.

Some cases of abuse and dependence on carisoprodol have been reported when the patient is used for a long time and has a history of drug abuse. The detoxification symptom has been reported when used for prolonged carisoprodol and stops suddenly. Symptoms of detoxification include insomnia, vomiting, abdominal pain, headache, tremor, muscle convulsions, air conditioning, hallucinations, mental disorders. One of the metabolites of carisoprodol can also cause dependence.

To reduce the risk of abuse, it is necessary to assess the risk before prescribing. After prescribing, limit the treatment time within three weeks, keep the records carefully, monitor signs of abuse and overdose, and guide patients and families on abuse; Storage information and processing.

epilepsy

There has been a report that appears epilepsy when using carisoprodol. Most cases occur due to overdose, and use drugs and alcohol.

Use for children:

Efficiency, safety and pharmacokinetics of carisoprodol for children under 16 have not been established.

Used for elderly patients:

Efficiency, safety and pharmacokinetics of carisoprodol for patients over 65 have not been established.

Used for patients with renal failure:

Carisoprodol pharmacokinetics and safety in patients with renal failure has not been set. It should be noted when used for patients with impaired renal function due to carisoprodol is eliminated through the kidneys. Carisoprodol can be removed by hemorrhage and abdominal separation.

Used for patients with liver failure:

Carisoprodol pharmacokinetics and safety in patients with liver failure has not been set. It should be noted when used for patients with impaired liver function due to carisoprodol metabolized in the liver.

Used for patients with CYP2C19 activity decline:

Patients with CYPC219 impaired activity will be more exposed to carisoprodol. Therefore, it should be noted when using carisoprodol in these patients.

The effect of drugs on driving and operating machinery

Carisoprodol causes sedation and can reduce cognitive and/or exercise, so it is recommended that patients do not drive and operate machinery.

Use drugs for women during pregnancy and lactation

Pregnant women

There is no sufficient data on the use of carisoprodol during pregnancy. Animal studies show that carisoprodol passes through the placenta and causes adverse effects on the development of the fetus and after -birth survival.

The monster effect: Animal studies have not fully evaluated the teratogenic effect of carisoprodol. In mouse reproductive research, mice were treated with Meprobamat and rabbits showing no increase in the rate of birth defects. Post -marketing studies with pregnant subjects using Meprobamat shows that there is not enough evidence to prove that Meprobamat increases the risk of congenital malformation after exposure in the first 3 months of pregnancy. Cross studies show that there is an increase in the risk of inconsistent malformations.

Output effects: In animal studies, carisoprodol reduces the fetal weight, postpartum weight gain and postpartum survival rate at a dose of 1 - 1.5 times. Pregnant mice in contact with Meprobamat shows that the mouse is born to change behavior until maturity. For children when pregnant mothers use Meprobamat, a study does not detect adverse effects on intellectual development or behavioral development, or IQ.

Therefore, only use Biromonol for pregnant women only when benefits are greater than the risk.

There is no information on the effects of carisoprodol on mother and fetus during labor.

breastfeeding women

Restricted data shows that carisoprodol appears in milk and can reach a concentration of 2-4 times the concentration in plasma. 1 Report shows that babies appear 4-6% of daily doses of mother use and have no unwanted effects. However, the mother in the report of less milk and the child used more milk powder. In mice research, the survival rate and the weaning weight of the mouse decreased. This shows that the use of carisoprodol can lead to reduced or less nutritional effects of babies (by sedation) and/or reducing the amount of milk.

Be careful when using carisoprodol for nursing women.

Drug interaction

Central nervous system

It is possible to unite the sedative effect of carisoprodol and other central nervous inhibitors (such as alcohol, benzodiazepine, opium, three -round antidepressants). Therefore, be careful with patients who are using alcohol and/or central neurological inhibitors.

Do not use Carisoprodol and Meprobamate (a metabolic of carisoprodol).

Inhibition and induction CYP2C19

Carisoprodol is metabolized in the liver by CYP2C19 to form Meprobamat. Therefore, simultaneous use of carisoprodol with CYP2C19 inhibitors such as omeprazol or fluvoxamine can lead to increased carisoprodol risks and reducing Meprobamate response. Carisoprodol simultaneous use with CYP2C19 induction drugs such as rifampin can reduce carisoprodol's danger and increase Meprobamate response. Aspirin at low doses also shows the touch effect on CYP2C19.